← 2amccm.com blog

Thyrotoxicosis: Complete Learning Summary

Diagnosis · Disposition · Treatment · Thyroid Function Test (TFT) Pitfalls

2am Quick Look Up: Which Test, When

The two rules that drive every row below 1. Diagnose with TSH. Titrate thyrotoxicosis with FT4 + total T3 (in the ICU, FT4 alone; total T3 is unreliable there). After treatment starts, TSH can stay suppressed for months (in Graves often 3 months or longer) even when the patient is euthyroid or already hypothyroid. Adjusting MMI to a low TSH overtreats.[3]
2. Titrate primary hypothyroidism with TSH. Recheck 6 to 8 weeks after any levothyroxine dose change (it takes that long to reach steady state). Exception: central hypothyroidism, where TSH is useless; follow FT4.[13]

Table A · Initial diagnosis vs. what to follow, by condition

ConditionInitial diagnosisFollow for med adjustmentHow oftenWatch out
Thyrotoxicosis
Graves disease on MMI/PTU TSH, FT4, total T3, TRAb (or TSI). CBC w/diff + LFTs before ATD. FT4 + total T3. Add TSH once FT4/T3 normal. 4 to 6 wk until euthyroid, then q2 to 3 mo on maintenance. TRAb at 12 to 18 mo before trial off. TSH lags for months; don't chase it early. T3 can stay high while FT4 normalizes ("T3 predominant" Graves).
Graves after RAI As above (already diagnosed) FT4 + total T3, then TSH once on levothyroxine 1 to 2 mo after RAI, then q4 to 6 wk for ~6 mo Most become hypothyroid (the goal). Low TSH early after RAI does not mean still hyper.
After total thyroidectomy As above TSH (on levothyroxine). Calcium ± PTH post op. TSH at 6 to 8 wk after starting levothyroxine Starting dose ~1.6 μg/kg/day. Hypocalcemia from hypoparathyroidism in the first days.
Toxic adenoma / toxic MNG TSH, FT4, total T3, RAIU / scintigraphy (hot nodule or patchy uptake), thyroid US FT4 + total T3 4 to 6 wk on MMI; after RAI or surgery, 1 to 2 mo then q4 to 6 wk Often T3 toxicosis (normal FT4, high T3), so always order T3. Does not remit on ATD; definitive therapy is the plan.
Thyroiditis (painless, postpartum, subacute) TSH, FT4, total T3 (T3:T4 <20), low RAIU, TRAb negative. Subacute: ESR/CRP high, tender gland. TSH + FT4 q4 to 8 wk through the hyper phase, the hypo phase, and recovery (~6 mo) No ATDs (nothing to block; it's leakage). β-blocker for symptoms; NSAID or prednisone for subacute pain. Watch for permanent hypothyroidism.
Amiodarone induced (AIT) TSH, FT4, total T3, TRAb, thyroid US with Doppler (flow high in type 1, absent in type 2) FT4 + total T3 q4 to 6 wk Type 1: MMI. Type 2: prednisone. Mixed or unclear: both. RAIU usually low from the iodine load, so less helpful.
ICI thyroiditis TSH + FT4 (baseline before ICI) TSH + FT4 Every cycle or q4 to 6 wk on therapy Destructive: no ATDs. Often turns into permanent hypothyroidism within 1 to 3 months.
Subclinical hyperthyroidism Low TSH, normal FT4 and T3 TSH, FT4, total T3 Repeat in 6 to 12 wk to confirm (many resolve) Rule out steroids, dopamine, recovery from illness, first trimester. Treat if TSH <0.1 and age ≥65, AF, osteoporosis.
Hypothyroidism
Primary hypothyroidism on levothyroxine TSH high + FT4 (low = overt, normal = subclinical). TPO Ab if cause unclear. TSH 6 to 8 wk after any dose change; q6 to 12 mo once stable Draw timing vs. the morning dose matters for FT4 (falsely high right after a dose), not for TSH. Absorption drops with calcium, iron, PPIs, food.
Central (secondary) hypothyroidism Low FT4 with low or inappropriately normal TSH. Check other pituitary axes (AM cortisol first). FT4 (aim upper half of normal) 6 to 8 wk after dose change TSH is useless here. Replace cortisol before thyroid hormone if adrenal insufficiency.
Subclinical hypothyroidism High TSH, normal FT4. TPO Ab. TSH + FT4 Repeat in 6 to 12 wk to confirm, then q6 to 12 mo Rule out recovery from illness, macro TSH, assay interference. Treat usually if TSH >10 or pregnancy.
Special situations
Pregnancy, hyperthyroid Trimester specific TSH, FT4 (or total T4), TRAb FT4 (or total T4), aim at or just above the upper limit of normal q4 wk PTU 1st trimester, usually MMI after ~16 wk (individualize).[25] Lowest ATD dose; overtreating causes fetal hypothyroidism. TRAb at 18 to 22 wk.
Pregnancy, on levothyroxine TSH (trimester specific range) TSH q4 wk until ~20 wk, then once at ~30 wk Increase dose ~25 to 30% as soon as pregnancy confirmed (e.g., 2 extra doses per week).
Thyroid storm (ICU) TSH, FT4, total T3, TRAb. BWPS score. CBC, LFTs, cortisol. FT4 (FT3 as backup). Not total T3, not TSH. Daily to every 2 to 3 days while titrating Total T3 reads falsely low in critical illness (low binding proteins, nonthyroidal illness). Steroid taper is clinical, not FT4 driven. See Part 3, Lab Monitoring in the ICU.
Critically ill, no known thyroid disease Usually don't check unless thyroid disease is really suspected n/a Recheck 4 to 6 wk after recovery Nonthyroidal illness: low T3, then low TSH and FT4; TSH can overshoot high during recovery. Steroids and dopamine suppress TSH.

Table B · Long term monitoring: what to follow once the dose is set

SituationFollowHow oftenDose adjustmentRecheck sooner if
Hyperthyroid on antithyroid drug
MMI, titration phase FT4 + total T3 (TSH not yet useful) About every 4 to 6 wk When FT4 normalizes, usually cut the dose by approximately 30 to 50% Symptoms return, adherence questions, or any fever / sore throat (STAT CBC)
MMI, stable maintenance TSH + FT4 (± total T3) About every 2 to 3 mo; if on long term low dose MMI beyond ~18 mo, approximately every 4 to 6 mo Usually 5 to 10 mg/day; adjust in small steps (approximately 2.5 to 5 mg) New symptoms, pregnancy planned, new rash, jaundice, dark urine
Deciding to stop MMI TRAb + TSH + FT4 At about 12 to 18 mo of therapy TRAb normal: trial off is reasonable. Still high: probably continue, or plan RAI / surgery n/a
After stopping MMI (remission) TSH + FT4 + total T3 About every 1 to 3 mo for the first 6 mo, then every 3 to 6 mo for the first year, then at least yearly Relapse: restart MMI or move to definitive therapy Most relapses probably happen in the first year; recheck with any symptoms or pregnancy
After definitive therapy
After RAI FT4 + total T3 first, then TSH once on levothyroxine At 1 to 2 mo, then about every 4 to 6 wk until stable (approximately 6 mo); then yearly for life Start levothyroxine when FT4 falls below normal; then titrate by TSH Fatigue, weight gain, cold intolerance (likely hypothyroid)
After total thyroidectomy TSH 6 to 8 wk after starting levothyroxine, then every 6 to 12 mo once stable Start approximately 1.6 μg/kg/day; adjust by 12.5 to 25 μg Tingling or cramps early post op (check calcium)
Hypothyroid on levothyroxine
Primary hypothyroidism, titration TSH 6 to 8 wk after every dose change Adjust by approximately 12.5 to 25 μg; smaller steps if elderly or cardiac Palpitations or chest pain (possible overreplacement)
Primary hypothyroidism, stable TSH About every 12 mo (some check every 6 mo) Only if TSH out of range on repeat Pregnancy, weight change of approximately 10% or more, new estrogen, PPI, iron, calcium, or bile acid binder, malabsorption, age-related decline
Central hypothyroidism FT4 (TSH useless) 6 to 8 wk after a change, then every 6 to 12 mo Aim for the upper half of normal FT4 Pituitary changes, new glucocorticoid or growth hormone therapy
Watching without treatment
Subclinical hyperthyroidism (not treated) TSH, FT4, total T3 About every 6 to 12 mo Treat if it progresses or TSH stays below approximately 0.1 with risk factors New AF, bone loss, symptoms
Subclinical hypothyroidism (not treated) TSH (± FT4) About every 6 to 12 mo; probably yearly if TPO Ab positive Treat if TSH rises above approximately 10, symptoms, or pregnancy Pregnancy planned or confirmed
After thyroiditis recovers (painless, postpartum, subacute) TSH About yearly Levothyroxine if permanent hypothyroidism develops Future pregnancy (postpartum thyroiditis often recurs)
Drugs that affect the thyroid
Amiodarone TSH (± FT4, total T3) About every 3 to 6 mo on therapy; continue for approximately 6 to 12 mo after stopping Per type of dysfunction New palpitations, AF recurrence, weight loss
Lithium TSH Baseline, then about every 6 to 12 mo Levothyroxine if hypothyroid (lithium can usually continue) Goiter, fatigue, weight gain
Immune checkpoint inhibitor TSH + FT4 Every cycle or about every 4 to 6 wk on therapy, then periodically after Levothyroxine for hypothyroid phase; no ATDs Fatigue, palpitations, headache (consider hypophysitis: check cortisol)

Table C · Pattern decoder: what the TSH + FT4 + T3 combo means

TSHFT4T3ThinkNext step
↓↑↑Overt hyperthyroidismTRAb; RAIU only if TRAb negative
↓Normal↑T3 toxicosis (early Graves, toxic nodule)TRAb, RAIU / scintigraphy
↓NormalNormalSubclinical hyper, steroids, dopamine, recovering illness, 1st trimesterRepeat in 6 to 12 wk
↓ or normal↓↓Central hypothyroidism or nonthyroidal illnessAM cortisol, pituitary panel / MRI if not ICU
↑↓↓ or normalPrimary hypothyroidismStart levothyroxine; TPO Ab if cause unclear
↑NormalNormalSubclinical hypo, recovery from illness, macro TSHRepeat with TPO Ab in 6 to 12 wk
Normal or ↑↑↑ or normalDoesn't fit: biotin, heparin, heterophilic antibody, amiodarone, levothyroxine taken right before the draw, TSH-oma, thyroid hormone resistanceAsk about supplements and heparin; rerun on a different platform; then pituitary MRI

Table D · Cause of thyrotoxicosis at a glance

CauseTRAbT3:T4RAIUThyroglobulinClueATD helps?
Graves disease+>20High, diffuseHighEye disease, diffuse goiter, bruitYes
Toxic adenoma / MNG−>20Hot nodule / patchyHighPalpable nodule(s), older patientYes (bridge to RAI or surgery)
Painless / postpartum thyroiditis−<20LowHighWithin 12 mo postpartum, TPO Ab +No
Subacute (de Quervain)−<20LowHighPainful tender gland after viral illness, ESR/CRP highNo
Exogenous thyroid hormone−Depends on what was takenLowLowNo goiter; the only cause with low thyroglobulinNo (stop the source)
AIT type 1−VariableLow to normalHighPre-existing goiter; Doppler flow highYes
AIT type 2−VariableLowHighNormal gland; Doppler flow absentNo (prednisone)
ICI thyroiditis−<20LowHighOn anti PD-1 / CTLA-4No

T3:T4 ratio = total T3 (ng/dL) ÷ total T4 (μg/dL).

Part 1 — Initial Testing & Diagnostic Workup: "TSH First, Then Follow the Arrow"

Day 1 lab panel for suspected thyrotoxicosis TSH (thyroid-stimulating hormone), FT4 (free thyroxine), total T3 (triiodothyronine), TRAb (TSH receptor antibody) or TSI (thyroid-stimulating immunoglobulin), TPO Ab (thyroid peroxidase antibody), CBC w/diff, CMP (including LFTs). Add TgAb (thyroglobulin antibody) if cancer surveillance is relevant. RAIU (radioactive iodine uptake)/scintigraphy is not a first-line test — order only if TRAb is negative or if nodules are palpated.

Step 1 — TSH: the gatekeeper

This patient: TSH <0.005 → overt thyrotoxicosis confirmed.

Step 2 — Free Hormones: degree of thyrotoxicosis

This patient: FT4 3.63 (2.1× ULN (upper limit of normal)) + FT3 11.4 (2.6× ULN) + Total T3 303 (1.7× ULN) → overt hyperthyroidism. T3:T4 ratio >20:1, consistent with GD.

Step 3 — Antibody Testing: "why is this happening?"[2]

AntibodyTarget / meaningClinical use
TRAb Antibody against the TSH receptor — encompasses stimulating, blocking, and neutral forms Pathognomonic for Graves disease — sensitivity 97.7%, specificity 99.5%. If positive, no imaging needed. Single most useful test in suspected GD.
TSI Functional subset of TRAb that specifically stimulates the TSH receptor (bioassay) Correlates with Graves ophthalmopathy (GO) severity. Predicts recurrence risk after ATD (antithyroid drug) course. Useful when TRAb is borderline or when monitoring GO activity.
TPO Ab Antibody against thyroid peroxidase enzyme Marker of autoimmune thyroid disease broadly — present in ~75% of GD, ~95% of Hashimoto, and ~10% of the general population. Confirms autoimmunity but not specific to GD.
TgAb Antibody against thyroglobulin Another autoimmune marker; less diagnostically useful. Critical post-thyroidectomy for cancer surveillance — interferes with Tg (thyroglobulin) assays and must be measured alongside Tg.

When to order which:

This patient: TRAb 11.60 (6.6× ULN) and TSI 7.83 (14× ULN) → GD confirmed, no imaging needed. TPO Ab 249 and TgAb 13.9 confirm autoimmune thyroid disease but add no diagnostic specificity beyond TRAb. High TSI predicts low remission likelihood after a course of ATD — early discussion of definitive therapy is warranted.

Step 4 — RAIU / Scintigraphy: only if TRAb negative or nodules palpated

This patient: TRAb/TSI positive → scintigraphy not needed.
Pitfall reminder: high-dose biotin (>100 mg/day, but interference possible at ≥10 mg/day) can cause falsely low TSH and falsely high FT4/T3/TRAb — always ask about supplements if results don't match the clinical picture. See Part 5 for the full TFT interference framework.[8][2]

Part 2 — Inpatient vs. Outpatient Is a Clinical Decision, Not a Lab Decision

Thyroid hormone levels in thyroid storm are indistinguishable from those in compensated thyrotoxicosis.[1][2] The Burch-Wartofsky Point Scale (BWPS) — the standard scoring system for thyroid storm — is based entirely on clinical parameters with zero laboratory criteria.[3]

This patient: FT4 3.63 (>2× ULN) and FT3 11.4 (>2.5× ULN) — markedly elevated. But if the patient is sitting in clinic with HR 95, no fever, no AMS, no GI symptoms, and no CHF → outpatient management. The same labs in a patient with HR 140, temp 103°F, agitation, and vomiting → ICU admission for thyroid storm.

BWPS Categories

(≥45 = thyroid storm; 25–44 = impending storm; <25 unlikely)[3]

CategoryGradations
Temperature°F (graded bands from 99 to ≥104)
CNS effectsabsent → mild agitation → moderate (delirium, psychosis, extreme lethargy) → severe (seizure, coma)
GI-hepatic dysfunctionabsent → moderate (diarrhea, N/V, abdominal pain) → severe (unexplained jaundice)
Heart ratebpm (graded bands from 99 to ≥140)
CHFabsent → mild (pedal edema) → moderate (bibasilar rales) → severe (pulmonary edema)
Atrial fibrillationpresent or absent
Precipitating eventpresent or absent

Indications for Inpatient Management (clinical, not lab-based)[3][4]

Part 3 — Treatment Algorithm: Block, Brake, Boost, Bind, Break

5 B's Block (β-blocker) · Brake (ATD) · Boost (steroids) · Bind (iodine/cholestyramine) · Break (RAI (radioactive iodine)/thyroidectomy)

Block and Brake are used in every case. Boost and Bind are add-ons for severe/refractory disease. Break is definitive therapy.[1][2]


Pathway A — Outpatient (Compensated Thyrotoxicosis)

Step 1: BLOCK — β-Blocker

Symptom control. Propranolol at doses ≥160 mg/day may additionally inhibit peripheral T4-to-T3 conversion by approximately 20–30%, though this is probably of limited clinical significance at usual doses; its main benefit is nonselective symptom control.[2][3][8]

AgentDoseFrequencyKey features
Propranolol (preferred)10–40 mg start; up to 320 mg/dayTID–QIDNonselective; may modestly block T4→T3 at high doses (probably minor clinically)
Propranolol LA60–160 mgOnce dailyBetter adherence; same drug
Atenolol25–100 mgQD–BIDβ1-selective; avoid in pregnancy
Metoprolol25–50 mgBID–TIDβ1-selective; widely available
Nadolol40–160 mgOnce dailyNonselective; may block T4→T3

When β-blockers contraindicated (asthma, decompensated CHF, bradyarrhythmia, Raynaud) → non-DHP CCB (non-dihydropyridine calcium channel blocker):[3][5]

Step 2: BRAKE — Antithyroid Drug (ATD)

Methimazole (MMI) is first-line over propylthiouracil (PTU) for three reasons:[2][6]

  1. Better efficacy — faster normalization of FT4, FT3, TSH in RCT meta-analysis
  2. Once-daily dosing — MMI t½ (half-life) ~6 hr vs PTU ~1.5 hr
  3. Safer liver profile — PTU carries FDA boxed warning for fulminant hepatic necrosis (~2.7%); MMI hepatotoxicity is typically cholestatic and reversible (~0.4%)
When to use PTU instead: first trimester of pregnancy (MMI embryopathy: aplasia cutis, choanal/esophageal atresia); thyroid storm (PTU additionally blocks T4→T3 conversion, though recent comparative effectiveness data show no mortality or adverse event difference, so this is probably more tradition than proven benefit[26][27]); MMI allergy/intolerance.[2]

MMI Starting Dose by FT4 Severity

This patient: FT4 3.63 / ULN 1.77 = 2.1× ULN → start MMI 30–40 mg/day.
FT4 levelMMI starting doseThis patient?
1.0–1.5× ULN5–10 mg/day—
1.5–2.0× ULN10–20 mg/day—
2.0–3.0× ULN30–40 mg/day✓ FT4 3.63 = 2.1× ULN
>3.0× ULN (severe)40–60 mg/dayconsider inpatient

Before starting any ATD: baseline CBC w/diff and LFTs — not to preclude treatment, but as a reference for later agranulocytosis (0.2–0.5% risk, highest in first 90 days, peak approximately 1–2 months) or hepatotoxicity questions.[2][6]

This patient: 4/20 labs show AST 229 / ALT 184 — thyrotoxic hepatitis, not baseline liver disease. By 5/11 they normalized (AST 21, ALT 33). The 5/11 values serve as true pre-ATD baseline. ANC 3.0 on 5/11 is a good baseline — if it drops below 1.0 on ATD, that is concerning; below 0.5 = agranulocytosis → stop drug immediately.

Titration Method (Maintenance Dosing)

The standard approach is the titration method — preferred over "block-and-replace" because the latter requires higher ATD doses with more side effects and no proven benefit.[1][4]

  1. Start MMI 20 mg BID (40 mg/day) given the severity
  2. At 4–6 weeks, if FT4 trending toward normal → reduce to 20 mg once daily
  3. At 8–12 weeks, if FT4 and T3 normalizing and TSH recovering → reduce to 10 mg/day
  4. Goal: maintenance dose of 5–10 mg/day by ~6 months[2][3]
  5. If FT4/T3 not improving at 4–6 weeks, ensure adherence before increasing dose — non-adherence is the most common cause of treatment failure[2]

Patient Counseling — When to Stop MMI and Call Immediately

A survey found that 61% of patients on ATDs were unfamiliar with the symptoms of agranulocytosis.[2] Communicate clearly — ideally both verbally and in writing.

STOP MMI immediately and go to the ER / call the office if any of the following occur[1][2][5]
"FAST" mnemonic for patients:
  • F — Fever (especially >101°F / 38.3°C with no obvious cause)
  • A — Aching throat (severe sore throat, difficulty swallowing — the hallmark of agranulocytosis)
  • S — Skin turning yellow (jaundice — hepatotoxicity) or dark urine (tea/cola-colored)
  • T — Terrible rash (widespread, blistering, or not responding to antihistamines)

What Happens at the ER

STAT CBC with differential and LFTs.[1][2]

FindingAction
ANC <0.5 × 10⁹/L = agranulocytosisStop MMI permanently; admit; broad-spectrum antibiotics; G-CSF (granulocyte colony-stimulating factor)
ANC <1.0 but >0.5Concerning — hold drug, recheck in 24–48 hours
LFTs: hepatocellular injury (AST/ALT >3× ULN or rising bilirubin)Stop MMI; do not rechallenge
Timing of highest risk The first 90 days after starting MMI carry the highest risk for both agranulocytosis and hepatotoxicity, with onset probably peaking at approximately 1–2 months. After 90 days, risk drops substantially but does not reach zero — agranulocytosis can occur on re-exposure even after years.[1][2]

Additional Counseling Points

Duration: treat 12–18 months, then check TRAb — if normalized, trial off. Remission rate ~40–50%. Long-term low-dose MMI is safe if remission not achieved.[2]

This patient: TRAb 11.60 (>6× ULN) before starting ATD is an independent predictor of recurrence — remission likelihood is low. Early discussion of definitive therapy is warranted.[2]

Optional Outpatient Add-on — BIND (cholestyramine)

For patients needing faster hormone reduction: cholestyramine 4 g PO BID–QID (even 1–2 g BID effective) binds T4/T3 in the gut, interrupting enterohepatic recirculation. At 4 weeks, significant additional FT4 reduction (mean diff −1.0 ng/dL) vs standard therapy alone.[7]


Pathway B — Inpatient (Thyroid Storm / Severe Thyrotoxicosis)

All steps initiated simultaneously, with one critical timing exception noted.[3][4]

Step 1: BLOCK — IV β-Blocker

Avoid aspirin/salicylates for fever — they displace T4 from TBG (thyroxine-binding globulin), increasing free T4. Use acetaminophen + cooling blankets.[3][4]

Step 2: BRAKE — High-dose ATD

Step 3: BIND (iodine) — SSKI (saturated solution of potassium iodide)

⚠️ Must wait ≥1 hour after the first ATD dose. Giving iodine before ATD provides substrate for new hormone synthesis (escape from Wolff-Chaikoff effect).[3]

Step 4: BOOST — Glucocorticoids

Glucocorticoid Choice for T4→T3 Blockade

Dexamethasone has the best-documented and most potent inhibition of peripheral T4-to-T3 conversion among glucocorticoids. Dexamethasone 8 mg/day reduces serum T3 by 37–50% in Graves disease, with T3 beginning to fall at 24 hours and remaining suppressed for ≥5 days.[22] This effect is explicitly "exploited therapeutically" in severe thyrotoxicosis.[8]

SteroidT4→T3 blockadeDose studiedT3 reduction
DexamethasoneStrong, well-documented2 mg q6h (8 mg/day)30–50%
HydrocortisoneProbable, less well-characterized — ATA says it "may" block T4→T3300 mg load → 100 mg q8hNot well quantified
PrednisoneMinimal at standard doses20 mg/dayNo significant change

FDA levothyroxine labeling cites glucocorticoids ≥dexamethasone 4 mg/day as the threshold for the ~30% T3 reduction class effect. Methylprednisolone and betamethasone aren't specifically studied for this indication, but high-potency synthetic glucocorticoids at supraphysiologic doses are expected to share the effect — higher potency and higher dose correlate with greater inhibition of peripheral deiodination.[21]

Bottom line For T4→T3 blockade specifically: dexamethasone 2 mg IV/PO q6h. For adrenal insufficiency prophylaxis as the primary concern: hydrocortisone. Prednisone at standard doses doesn't reliably reduce T3 — don't substitute it for either.

Practical Dexamethasone Algorithm

There is no published, standardized dexamethasone taper protocol for thyroid storm in any guideline — ATA and expert reviews simply say "taper and discontinue once clinical improvement occurs."[3][21] A reasonable decision-tree:

TimepointStateAction
Day 0Initial storm managementDexamethasone 2 mg IV q6h + PTU + propranolol + SSKI (≥1 hr after PTU)
Day 2–3Improving (↓HR, ↓temp, AMS clearing)Begin taper: 2 mg q12h × 1 d → 2 mg daily × 1 d → stop
Day 2–3NOT improvingContinue full dose; consider TPE or emergency thyroidectomy

Typical total course ≤ 5 days. Taper is based on clinical improvement, not a specific FT4 or TSH cutoff. Dexamethasone serves two time-limited purposes (T4→T3 blockade + coverage for relative adrenal insufficiency); prolonged courses don't add benefit and carry the usual steroid risks.

Why a short course is safe

Preoperative preparation for emergency thyroidectomy: dexamethasone should be tapered within the first 72 hours after surgery.[21] Panzer et al. used a lower-dose regimen (dexamethasone 1 mg BID) in combination with iopanoic acid and thionamides for rapid preoperative preparation, continuing until patients were clinically euthyroid — typically days to a couple of weeks.[24]

Step 5: BIND — Cholestyramine

Step 6: RESCUE — If refractory

Supportive: cooling blankets (not aspirin), volume resuscitation, antibiotics if infection is precipitant, nutritional support, ICU monitoring.[3][4]

Lab Monitoring in the ICU

MarkerUse in the ICU
Free T4Primary trending marker. Most reliable in the ICU; less affected by binding-protein changes than total T3.
Free T3Reasonable secondary marker despite assay imprecision (see below).
Total T3Do NOT rely on this in the ICU. Confounded by low binding proteins (TBG, albumin) and NTIS (non-thyroidal illness syndrome). Can read paradoxically low despite active thyrotoxicosis.
TSHUseless acutely — stays suppressed for weeks to months after thyrotoxicosis resolves.
Why total T3 is misleading in the ICU Total T3 = protein-bound + free T3 (~99.7% bound). In the ICU, TBG and albumin drop (inflammation, malnutrition, hepatic dysfunction, capillary leak) → disproportionate fall in total T3 even when the thyroid is overproducing. NTIS layers on top: ↓D1 deiodinase + ↑D3 deiodinase activity → less T3 production from T4. Total T3 can read low while the patient is actively thyrotoxic.
Illustrative ICU snapshot: total T3 70.7 ng/dL (low/normal) with FT3 4.82 pg/mL (elevated) and FT4 3.92 ng/dL (markedly elevated). The free fractions tell the real story; the total T3 has been "consumed" by binding-protein loss. Trust the free fractions; ignore the total.
Why free T3 is imperfect but better than total T3 in the ICU ATA recommends total T3 over FT3 for general practice because of FT3's assay imprecision. The opposite is true in the ICU: binding-protein confounding of total T3 is a bigger problem than FT3 assay imprecision. FFAs, heparin, and ICU drugs can artifactually elevate FT3 on immunoassay, but in discordant cases FT3 still better reflects clinical features and TSH/FT4 than total T3 (Castilho et al. 2026). Bottom line: in ICU thyrotoxicosis, FT3 > total T3 for monitoring, but FT4 remains the primary trending lab.

FT4 Goals


Pathway C — Preoperative Preparation (Elective Thyroidectomy)[2]

  1. Render euthyroid with MMI (1–3 months)
  2. Add SSKI 2–3 drops PO TID for 7–10 days preop (reduces thyroid vascularity)
  3. Continue β-blocker perioperatively
  4. If cannot render euthyroid (ATD allergy, urgent): β-blocker + SSKI + dex 2 mg QID + cholestyramine 4 g QID

Definitive Therapy — BREAK[2][3]

Both RAI and total thyroidectomy are equally effective at curing Graves disease (definitive cure >90%). The choice is driven by patient anatomy, comorbidities, GO status, pregnancy plans, and patient preference. Both render the patient hypothyroid (intentional in GD) and both require lifelong levothyroxine.

Choosing Between RAI and Thyroidectomy — Stable / Outpatient Patient

FactorFavors RAIFavors thyroidectomy
Goiter sizeSmall to moderate (<80 g)Large (≥80 g) — RAI less effective; compressive symptoms (dyspnea, dysphagia, stridor)
NodulesNone suspiciousSuspicious nodule on US/FNA requiring histology
Graves ophthalmopathyNone or mild/inactiveModerate-severe active GO, especially in smokers (RAI can worsen GO)
TRAb levelLow to moderateVery high TRAb — predicts RAI failure
Pregnancy plansNot planning within 6–12 monthsPregnancy planned <6–12 months; pregnant in 2nd-3rd trimester
Coexisting hyperparathyroidism—Combined parathyroidectomy + thyroidectomy in one operation
Surgical / anesthesia riskHigh cardiopulmonary riskAcceptable surgical risk
Access to surgeonNo experienced thyroid surgeon availableHigh-volume thyroid surgeon available — complication rates depend heavily on surgeon volume
Speed of resolutionOK with weeks-to-monthsNeed rapid, immediate control
Patient preferenceAvoid surgery / scarAvoid radiation exposure; want definitive same-day control
Cost / logisticsLower cost; outpatient single visitHigher cost; OR + inpatient stay

Complications

ApproachRisks
RAIPermanent hypothyroidism (expected, requires lifelong levothyroxine); worsening of active GO (use prednisone prophylaxis if active GO, especially in smokers); transient radiation thyroiditis with worsening thyrotoxicosis (1–3%); rare salivary gland damage; pregnancy/breastfeeding contraindicated 6–12 months
Total thyroidectomyTransient hypoparathyroidism (~10–20%); permanent hypoparathyroidism (1–4%); RLN injury (1–4%); permanent hypothyroidism (100%); general surgical/anesthesia risks; complication rates strongly dependent on surgeon volume

ICU / Thyroid Storm Setting

⚠️ RAI is contraindicated in acute thyroid storm or in the critically ill hospitalized patient. RAI can precipitate storm via transient radiation thyroiditis. Reasons against acute use: (1) takes weeks-to-months to work — useless for acute crisis; (2) the radiation thyroiditis release can worsen — or precipitate — storm; (3) patient should be euthyroid before treatment for safety.

In the ICU/storm setting, the only definitive option is emergency total thyroidectomy, reserved for:

Bridge to OR: β-blocker + iodine (SSKI) + dexamethasone + cholestyramine ± TPE. The Panzer protocol (iopanoic acid + dexamethasone + thionamide) is used at experienced centers for rapid preoperative preparation.[24] Emergency thyroidectomy in the storm setting historically carried 10–30% mortality but is substantially lower at high-volume centers with multidisciplinary preparation.[4]

Definitive therapy after recovery: plan RAI or thyroidectomy as an outpatient once the patient is euthyroid on ATDs and the iodine load has washed out — typically 2–6 weeks after stopping SSKI, since residual iodine reduces RAI uptake and effectiveness.

Part 4 — Drug Side Effects

DrugCommonSerious / rareMonitoring
MMI Rash/urticaria (6%), arthralgias (1–5%), GI upset, taste/smell changes Agranulocytosis (0.2–0.5%, highest first 90 days, peak ~1–2 mo); cholestatic hepatitis (0.4%); pancreatitis; embryopathy (1st trimester) Baseline CBC + LFTs; symptom-based (fever/sore throat → STAT CBC)
PTU Rash/urticaria (3%), arthralgias, GI upset ⚠️ FDA boxed warning: fulminant hepatic necrosis (2.7%); agranulocytosis (0.2–0.5%); ANCA (anti-neutrophil cytoplasmic antibody)-positive vasculitis (up to 3%, increases with duration) Baseline CBC + LFTs; symptom-based
Propranolol Fatigue, cold extremities, bradycardia, dizziness, GI upset Bronchospasm, severe bradycardia, hypotension, masking of hypoglycemia, depression HR/BP; glucose in diabetics
Esmolol (IV) Hypotension (dose-dependent), injection site reactions Severe bradycardia, bronchospasm Continuous HR/BP (ICU)
Diltiazem Bradycardia, hypotension, peripheral edema, constipation, dizziness AV block, severe hypotension (esp. with β-blocker combo), worsening CHF HR, BP, ECG
Verapamil Same as diltiazem + more constipation Stronger negative inotropy — avoid in HFrEF; AV block HR, BP, ECG, LV function
SSKI / KI (potassium iodide) Metallic taste, nausea, sialadenitis, acneiform rash Iodine hypersensitivity (rare); escape from Wolff-Chaikoff after 1–2 wk; ⚠️ give ≥1 hr after ATD TFTs; limit to 7–14 days in storm
Hydrocortisone Hyperglycemia, fluid retention, insomnia, GI upset Adrenal suppression (prolonged), infection risk, GI bleed, psychosis (high dose) Glucose; taper when storm resolves
Dexamethasone Hyperglycemia, insomnia, mood changes Same as HCT (hydrocortisone) but no mineralocorticoid effect (less fluid); adrenal suppression Glucose
Cholestyramine Constipation (most common), bloating, abdominal discomfort, nausea Impaired absorption of other drugs (separate by 1 hr before / 4 hr after); fat-soluble vitamin malabsorption (A, D, E, K) with prolonged use Timing of other meds; stool frequency
RAI Transient neck pain/swelling, radiation thyroiditis (1–3%), transient worsening of thyrotoxicosis Permanent hypothyroidism (expected in GD); worsening of GO — steroid prophylaxis if active GO; rare salivary damage TFTs q4–6 wk post-RAI; lifelong levothyroxine
This patient — monitoring plan: baseline ANC 3.0 (5/11) and ALT 33 / AST 21 (5/11, post-resolution of thyrotoxic hepatitis). If started on MMI 30 mg/day: (1) any fever/sore throat → STAT CBC r/o agranulocytosis; (2) jaundice/dark urine → STAT LFTs; (3) glucose 122 and A1c 5.7 should be rechecked after euthyroidism to determine if truly prediabetic or thyrotoxic hyperglycemia.

Part 5 — Drugs and Supplements That Interfere with TFTs

Critical section — these substances cause spurious TFT results in euthyroid patients, leading to misdiagnosis and inappropriate treatment. Over 50% of documented thyroid assay interferences have led to misdiagnosis and/or inappropriate management.[9]

Category A — Assay Interference (patient is euthyroid; labs are wrong)[8]

SubstanceTSHFT4T3Condition mimickedMechanism / what to do
Biotin (vit B7) ↓ falsely low ↑ falsely high ↑ falsely high Primary hyperthyroidism (can cause false-positive TRAb) Competes with biotinylated reagents in streptavidin-biotin immunoassays. Stop ≥2–7 days before retest; interference possible at doses as low as 10 mg/day
Heparin / enoxaparin Normal ↑ falsely high ↑ falsely high TSH-oma, thyroid hormone resistance Generates FFAs (free fatty acids) in vitro that displace T4 from binding proteins. Draw blood before heparin dose; analyze immediately
Heterophilic antibodies (e.g., HAMA, human anti-mouse antibodies) ↑ or ↓ Variable Variable Various Cross-react with assay antibodies. Method comparison on different platform; heterophilic blocking reagents
Macro-TSH ↑ falsely high Normal Normal Subclinical hypothyroidism (~1% of cases) TSH bound to immunoglobulins; cleared slowly. PEG (polyethylene glycol) precipitation; gel filtration
Biotin deserves special emphasis. OTC (over-the-counter) supplements marketed for hair/nails typically contain 5–10 mg (167–333× the RDI (recommended daily intake) of 30 μg). High-dose biotin (300 mg/day) used for MS (multiple sclerosis) causes dramatic interference. The pattern — low TSH, high FT4, high T3, and even false-positive TRAb — perfectly mimics Graves disease and has led to unnecessary ATD treatment and RAI.[8][14][15]
This patient: always ask about biotin and other supplements before interpreting TFTs. Here the clinical picture (tachycardia, tremor, weight loss) matched the labs, and TRAb/TSI were markedly positive — making biotin interference extremely unlikely. But if a patient has "Graves labs" with no symptoms, biotin interference should be the first consideration.

Category B — Drugs That Cause TRUE Thyroid Dysfunction (labs are correct)[2][8][12][17]

DrugThyroid effectMechanismMonitoring
Amiodarone Hypothyroidism (13–17%) or thyrotoxicosis (AIT (amiodarone-induced thyrotoxicosis), 9%); 5-yr cumulative ~40% AIT type 1: iodine excess → ↑ synthesis (pre-existing goiter); AIT type 2: destructive thyroiditis; hypothyroidism: direct toxicity + Wolff-Chaikoff TSH q3–6 mo on therapy, then q6 mo; continue 6–12 mo after stopping (t½ ~100 d)
Lithium Hypothyroidism (5–15%); goiter; rarely hyperthyroidism Inhibits iodine uptake, hormone synthesis, and release; ↑ thyroid autoimmunity TSH baseline, q6–12 mo
ICIs (immune checkpoint inhibitors) (anti-PD-1 (programmed cell death protein-1), anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein-4)) Thyrotoxicosis (transient, destructive) → often evolves to hypothyroidism (50–90%); most common endocrine irAE (immune-related adverse event) Cytotoxic T-cell-mediated thyroid destruction; ATDs NOT indicated (destructive, not synthetic) TSH + FT4 q4–6 wk during therapy
TKIs (tyrosine kinase inhibitors) (sunitinib, sorafenib) Hypothyroidism (up to 27%) Destructive thyroiditis; impaired iodine uptake; capillary regression TSH q4–8 wk
Interferon-α Hypo- or hyperthyroidism; autoimmune thyroiditis Autoimmune TSH q3 mo during therapy
Alemtuzumab Graves disease in up to 30–40% Immune reconstitution → autoimmune GD TSH q3 mo for 4 yr after last dose

Category C — Altered Binding, Metabolism, or Absorption (labs change; clinical significance varies)

Drug / classEffect on TFTsMechanismClinical significance
Oral estrogen (OCP (oral contraceptive pill), HRT (hormone replacement therapy)) ↑ Total T4/T3 (FT4 usually normal) ↑ TBG production (hepatic first-pass) Patients on levothyroxine may need dose increase; transdermal estrogen has minimal effect
Androgens, glucocorticoids, niacin ↓ Total T4/T3 (FT4 usually normal) ↓ TBG production Rarely clinically significant; glucocorticoids also suppress TSH centrally
Phenytoin, carbamazepine ↓ FT4 (assay artifact); normal TSH Displace T4 from binding proteins + enhance T4 metabolism via CYP (cytochrome P450) induction Artifactually low FT4 mimics central hypothyroidism — patient is euthyroid; levothyroxine dose may need increase
Salsalate ↓ FT4; normal TSH Displaces T4 from binding proteins Same artifact as phenytoin — patient is euthyroid
Cholestyramine, colestipol ↓ T4/T3 levels Binds thyroid hormone in gut; impairs levothyroxine absorption Separate levothyroxine dosing by ≥4 hours
Metformin ↓ TSH in hypothyroid patients Unclear; may enhance TSH suppression May cause apparent "improvement" in subclinical hypothyroidism — not a true thyroid effect
Glucocorticoids (high dose) ↓ TSH; ↓ T3 Central TSH suppression + inhibit T4→T3 conversion Can mimic central hypothyroidism or mask thyrotoxicosis; dose-dependent and reversible
Quick rule of thumb If the clinical picture does not match the labs → suspect assay interference or drug effect. Most common culprits to ask about: biotin supplements, heparin (recent administration), amiodarone, lithium, ICIs, estrogen, antiepileptics.[8][9][12]

Part 6 — Case Comments

Confirmed Graves disease — TRAb 11.60 and TSI 7.83 are both markedly elevated, confirming the diagnosis without need for imaging.[2]

Thyrotoxic hepatitis — AST 229 → 21 and ALT 184 → 33 normalization without liver-directed therapy is classic. The hepatocellular pattern (AST/ALT predominant) is the typical thyrotoxic pattern, distinct from the cholestatic pattern of MMI-induced hepatotoxicity. This means the 5/11 labs (post-resolution) — not the 4/20 labs — serve as the true pre-ATD baseline.

Abbreviations

Thyroid- and specialty-specific terms only. Universal medical abbreviations (TSH, FT4, BID, IV, ICU, HR, BP, ECG, AST, ALT, CBC, etc.) are not listed.

AbbreviationExpansionAbbreviationExpansion
AITAmiodarone-induced thyrotoxicosisNTISNon-thyroidal illness syndrome
ANCAAnti-neutrophil cytoplasmic antibodyOCPOral contraceptive pill
ATDAntithyroid drugPD-1Programmed cell death protein-1
BWPSBurch-Wartofsky Point ScalePEGPolyethylene glycol
CCBCalcium channel blockerPTUPropylthiouracil
CTLA-4Cytotoxic T-lymphocyte-associated protein-4RAIRadioactive iodine
CYPCytochrome P450RAIURadioactive iodine uptake
DHPDihydropyridineRDIRecommended daily intake
FFAFree fatty acidRLNRecurrent laryngeal nerve
G-CSFGranulocyte colony-stimulating factorrT3Reverse triiodothyronine
GDGraves diseaseSSKISaturated solution of potassium iodide
GOGraves ophthalmopathyTBGThyroxine-binding globulin
HAMAHuman anti-mouse antibodiesTFTThyroid function test
HCTHydrocortisoneTgThyroglobulin
HFrEFHeart failure with reduced ejection fractionTgAbThyroglobulin antibody
HPAHypothalamic-pituitary-adrenal (axis)TKITyrosine kinase inhibitor
HRTHormone replacement therapyTPETherapeutic plasma exchange
ICIImmune checkpoint inhibitorTPO AbThyroid peroxidase antibody
irAEImmune-related adverse eventTRAbTSH receptor antibody
KIPotassium iodideTSH-omaTSH-secreting pituitary adenoma
LALong-actingTSIThyroid-stimulating immunoglobulin
MMIMethimazoleULNUpper limit of normal
MNGMultinodular goiterWPWWolff-Parkinson-White
MSMultiple sclerosist½Half-life

References

  1. Wiersinga WM, Poppe KG, Effraimidis G. Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes Endocrinol. 2023;11(4):282–298.
  2. Lee SY, Pearce EN. Hyperthyroidism: a review. JAMA. 2023;330(15):1472–1483.
  3. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–1421.
  4. Kopp PA, Giordani I, Feldt-Rasmussen U, Forget-Renaud A. Approach to the patient with thyroid storm. J Clin Endocrinol Metab. 2026;111(5):1484–1494.
  5. Joglar JA, Chung MK, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. J Am Coll Cardiol. 2024;83(1):109–279.
  6. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388(10047):906–918.
  7. Moreno Watashi D, Sehgal A, Tejada Frisancho F, et al. Efficacy and safety of adjunctive bile acid sequestrant therapy for thyrotoxicosis: a systematic review and meta-analysis of RCTs. Thyroid. 2026;36(1):17–24.
  8. Burch HB. Drug effects on the thyroid. N Engl J Med. 2019;381(8):749–761.
  9. Favresse J, Burlacu MC, Maiter D, Gruson D. Interferences with thyroid function immunoassays: clinical implications and detection algorithm. Endocr Rev. 2018;39(5):830–850.
  10. Ylli D, Soldin SJ, Stolze B, et al. Biotin interference in assays for thyroid hormones, thyrotropin and thyroglobulin. Thyroid. 2021;31(8):1160–1170.
  11. Van Uytfanghe K, Ehrenkranz J, Halsall D, et al. TSH and thyroid hormones (T3 and T4): an ATA-commissioned review of current clinical and laboratory status. Thyroid. 2023;33(9):1013–1028.
  12. Al-Bahadili H, Powers Carson J, Markov A, Jasim S. The complex web of interferences with thyroid function tests. Endocr Pract. 2025;31(1):92–101.
  13. Taylor PN, Medici MM, Hubalewska-Dydejczyk A, Boelaert K. Hypothyroidism. Lancet. 2024;404(10460):1347–1364.
  14. Elston MS, Sehgal S, Du Toit S, Yarndley T, Conaglen JV. Factitious Graves disease due to biotin immunoassay interference — a case and review of the literature. J Clin Endocrinol Metab. 2016;101(9):3251–3255.
  15. Charles S, Agrawal N, Blum M. Erroneous thyroid diagnosis due to over-the-counter biotin. Nutrition. 2019;57:257–258.
  16. Li D, Radulescu A, Shrestha RT, et al. Association of biotin ingestion with performance of hormone and nonhormone assays in healthy adults. JAMA. 2017;318(12):1150–1160.
  17. Martinez Quintero B, Yazbeck C, Sweeney LB. Thyroiditis: evaluation and treatment. Am Fam Physician. 2021;104(6):609–617.
  18. Guðjónsson P, Jóhannesson AJ, Eyþórsson E, Andersen K. Amiodarone-induced thyroid dysfunction: a high cumulative incidence in a nationwide cohort study in Iceland. J Intern Med. 2025.
  19. National Comprehensive Cancer Network. Management of immune checkpoint inhibitor-related toxicities. Updated 2025-10-23.
  20. Kalra S, Aggarwal S, Khandelwal D. Thyroid dysfunction and dysmetabolic syndrome: the need for enhanced thyrovigilance strategies. Int J Endocrinol. 2021;2021:9641846.
  21. Suwansaksri N, Preechasuk L, Kunavisarut T. Nonthionamide drugs for the treatment of hyperthyroidism: from present to future. Int J Endocrinol. 2018;2018:5794054.
  22. Chopra IJ, Williams DE, Orgiazzi J, Solomon DH. Opposite effects of dexamethasone on serum concentrations of 3,3',5'-triiodothyronine (reverse T3) and 3,3',5-triiodothyronine (T3). J Clin Endocrinol Metab. 1975;41(5):911–920.
  23. Beuschlein F, Else T, Bancos I, et al. European Society of Endocrinology and Endocrine Society joint clinical guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency. J Clin Endocrinol Metab. 2024;109(7):1657–1683.
  24. Panzer C, Beazley R, Braverman L. Rapid preoperative preparation for severe hyperthyroid Graves disease. J Clin Endocrinol Metab. 2004;89(5):2142–2144.
  25. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017;27(3):315–389.
  26. Lee SY, Modzelewski KL, Law AC, Walkey AJ, Pearce EN, Bosch NA. Comparison of propylthiouracil vs methimazole for thyroid storm in critically ill patients. JAMA Netw Open. 2023;6(4):e238655.
  27. Satoh T, Isozaki O, Suzuki A, et al. 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (first edition). Endocr J. 2016;63(12):1025–1064.